RemeGen Co (FRA:REG) Other Long-Term Liabilities : €11.3 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is RemeGen Co Other Long-Term Liabilities?

RemeGen Co's other long-term liabilities for the quarter that ended in Dec. 2024 was €11.3 Mil.

RemeGen Co's quarterly other long-term liabilities increased from Dec. 2023 (€4.9 Mil) to Jun. 2024 (€5.0 Mil) and increased from Jun. 2024 (€5.0 Mil) to Dec. 2024 (€11.3 Mil).

RemeGen Co's annual other long-term liabilities declined from Dec. 2022 (€5.9 Mil) to Dec. 2023 (€4.9 Mil) but then increased from Dec. 2023 (€4.9 Mil) to Dec. 2024 (€11.3 Mil).

RemeGen Co Other Long-Term Liabilities Historical Data

The historical data trend for RemeGen Co's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Other Long-Term Liabilities Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Long-Term Liabilities

Get a 7-Day Free Trial

5.68

6.40

5.92

4.90

11.31

RemeGen Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Long-Term Liabilities	Get a 7-Day Free Trial								5.92	4.75	4.90	5.03	11.31

RemeGen Co Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

RemeGen Co Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (FRA:REG) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

09995:Hong Kong REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

https://www.remegen.com

RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.